WO2006029040A3 - Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof - Google Patents

Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof Download PDF

Info

Publication number
WO2006029040A3
WO2006029040A3 PCT/US2005/031447 US2005031447W WO2006029040A3 WO 2006029040 A3 WO2006029040 A3 WO 2006029040A3 US 2005031447 W US2005031447 W US 2005031447W WO 2006029040 A3 WO2006029040 A3 WO 2006029040A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
nuclear receptor
methods
transcription factors
receptor transcription
Prior art date
Application number
PCT/US2005/031447
Other languages
French (fr)
Other versions
WO2006029040A2 (en
Inventor
Charles C-Y Shih
Ching-Yuan Su
Original Assignee
Charles C-Y Shih
Ching-Yuan Su
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/045,181 external-priority patent/US20050209205A1/en
Application filed by Charles C-Y Shih, Ching-Yuan Su filed Critical Charles C-Y Shih
Priority to AU2005282624A priority Critical patent/AU2005282624A1/en
Priority to CA002578159A priority patent/CA2578159A1/en
Priority to MX2007002583A priority patent/MX2007002583A/en
Priority to EP05806820A priority patent/EP1804806A2/en
Priority to JP2007530424A priority patent/JP2008540327A/en
Publication of WO2006029040A2 publication Critical patent/WO2006029040A2/en
Publication of WO2006029040A3 publication Critical patent/WO2006029040A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention includes methods, compositions, cosmetics and pharmaceutical compositions for enhancing the degradation of a nuclear receptor (NR) or a STAT transcription factor protein. The methods, compositions, cosmetics and pharmaceuticals may be used to prevent or treat disorders or medical conditions that are at least in part affected by a nuclear receptor activation pathway or STAT activation pathway
PCT/US2005/031447 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof WO2006029040A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005282624A AU2005282624A1 (en) 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
CA002578159A CA2578159A1 (en) 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
MX2007002583A MX2007002583A (en) 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof.
EP05806820A EP1804806A2 (en) 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
JP2007530424A JP2008540327A (en) 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60667804P 2004-09-02 2004-09-02
US60/606,678 2004-09-02
US11/045,181 US20050209205A1 (en) 2004-01-28 2005-01-27 Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US11/045,181 2005-01-27

Publications (2)

Publication Number Publication Date
WO2006029040A2 WO2006029040A2 (en) 2006-03-16
WO2006029040A3 true WO2006029040A3 (en) 2008-12-04

Family

ID=36036907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031447 WO2006029040A2 (en) 2004-09-02 2005-09-02 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof

Country Status (6)

Country Link
EP (1) EP1804806A2 (en)
JP (1) JP2008540327A (en)
AU (1) AU2005282624A1 (en)
CA (1) CA2578159A1 (en)
MX (1) MX2007002583A (en)
WO (1) WO2006029040A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5292569B2 (en) * 2006-11-10 2013-09-18 国立大学法人名古屋大学 Anti-aging transcription factor activator and use thereof
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
WO2008085984A1 (en) 2007-01-08 2008-07-17 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
JP2010535213A (en) 2007-07-31 2010-11-18 アンドロサイエンス コーポレーション Compositions containing androgen receptor degradation (ARD) enhancers and methods for the prophylactic or therapeutic treatment of skin diseases and hair loss

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203933A1 (en) * 2002-04-17 2003-10-30 Kuo-Hsiung Lee Novel curcumin analogues and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2770842B1 (en) * 1997-11-13 1999-12-17 Oreal NOVEL COMPOUNDS DERIVED FROM N-ARYL 2-HYDROXY ALKYLAMIDES
CA2515589A1 (en) * 2003-02-11 2004-08-26 Warner-Lambert Company Llc Urea and thiourea derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203933A1 (en) * 2002-04-17 2003-10-30 Kuo-Hsiung Lee Novel curcumin analogues and uses thereof

Also Published As

Publication number Publication date
MX2007002583A (en) 2007-09-14
CA2578159A1 (en) 2006-03-16
AU2005282624A1 (en) 2006-03-16
WO2006029040A2 (en) 2006-03-16
EP1804806A2 (en) 2007-07-11
JP2008540327A (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2006128693A3 (en) 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
WO2008008359A3 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006119510A3 (en) Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007056366A3 (en) Compounds and compositions as ppar modulators
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2009038673A3 (en) Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
WO2010058926A3 (en) Pharmaceutical composition containing ginger extract or shogaol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 553478

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2578159

Country of ref document: CA

Ref document number: 2005282624

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007530424

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002583

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005282624

Country of ref document: AU

Date of ref document: 20050902

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005282624

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005806820

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005806820

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)